PLEASANTON, Calif., May 30, 2017 -- Natus Medical Incorporated (NASDAQ:BABY) today announced that Jim Hawkins, President and Chief Executive Officer, will present at the Jefferies 2017 Healthcare Conference in New York City. Mr. Hawkins is scheduled to present at 8:00 a.m. EDT on Tuesday, June 6, 2017.
Investors may listen to a live webcast and view a copy of the slide presentation online via the "Investors" section of the Company's web site at http://investor.natus.com. The recorded webcast will be accessible online for at least 30 days.
About Natus Medical Incorporated
Natus is a leading provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Additional information about Natus Medical can be found at www.natus.com.
Natus Medical Incorporated Jonathan A. Kennedy Executive Vice President and Chief Financial Officer (925) 223-6700 [email protected]


Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 



